RedHill Biopharma Ltd. (RDHL) Downgraded to “Sell” at Zacks Investment Research
RedHill Biopharma Ltd. (NASDAQ:RDHL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday.
According to Zacks, “RedHill Biopharma focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases, including cancer. RedHill’s proprietary pipeline includes: RHB-105 – a combination therapy for H.pylori infection; RHB-104 – a combination therapy for Crohn’s disease and multiple sclerosis; BEKINDA – a once-daily oral formulation of ondansetron for acute gastroenteritis and IBS-D; RHB-106 – an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals; YELIVA – an orally-administered first-in-class SK2 selective inhibitor targeting oncology, inflammatory and gastrointestinal indications; MESUPRON – a uPA inhibitor targeting gastrointestinal and other solid tumors; RP101 – currently subject to an option-to-acquire, Hsp27 inhibitor targeting gastrointestinal cancers; RIZAPORT – an oral thin film formulation of rizatriptan for acute migraines. “
RDHL has been the subject of several other research reports. FBR & Co reaffirmed a “buy” rating on shares of RedHill Biopharma in a research note on Wednesday. HC Wainwright set a $33.00 target price on shares of RedHill Biopharma and gave the stock a “buy” rating in a research note on Friday, October 7th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $26.25.
RedHill Biopharma (NASDAQ:RDHL) opened at 11.36 on Thursday. The company’s 50 day moving average is $0.00 and its 200 day moving average is $0.00. RedHill Biopharma has a 1-year low of $8.10 and a 1-year high of $16.54.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Van ECK Associates Corp raised its position in RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in RedHill Biopharma during the second quarter valued at approximately $142,000. Ingalls & Snyder LLC acquired a new position in RedHill Biopharma during the second quarter valued at approximately $451,000. Finally, Bank Hapoalim BM raised its position in RedHill Biopharma by 221.7% in the third quarter. Bank Hapoalim BM now owns 147,504 shares of the company’s stock valued at $2,049,000 after buying an additional 101,654 shares during the last quarter. 15.28% of the stock is owned by institutional investors and hedge funds.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd. is a biopharmaceutical company focused on the development and acquisition of late clinical-stage, orally administered drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. The Company’s products pipeline includes RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA (ABC294640), MESUPRON, RP101, RIZAPORT and RHB-101.
Receive News & Stock Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related stocks with our FREE daily email newsletter.